In the current study we demonstrate that progression of human urothelial and renal carcinomas is associated with increased expression of chemokine receptor CCR8. Up-regulated CCR8 expression was detected in peripheral and tumor-infiltrating myeloid cell subsets. At the functional level, we show that CD11b In this study we evaluated expression of CCR8 and its natural cognate ligand CCL1 in patients with urothelial carcinomas of bladder and renal cell carcinomas.
Statement of Translational Relevance
In the current study we demonstrate that progression of human urothelial and renal carcinomas is associated with increased expression of chemokine receptor CCR8. Up-regulated CCR8 expression was detected in peripheral and tumor-infiltrating myeloid cell subsets. At the functional level, we show that CD11b In this study we evaluated expression of CCR8 and its natural cognate ligand CCL1 in patients with urothelial carcinomas of bladder and renal cell carcinomas.
Experimental Design:
We examined CCR8 expression in peripheral blood and tumor tissues from patients with bladder and renal carcinomas. CCR8-positive myeloid cells were isolated from cancer tissues with magnetic beads and tested in vitro for cytokine production and ability to modulate T cell function.
Results:
We demonstrate that monocytic and granulocytic myeloid cell subsets in peripheral blood of cancer patients with urothelial and renal carcinomas display increased expression of chemokine receptor CCR8. Up-regulated expression of CCR8 is also detected within human cancer tissues and primarily limited to tumor-associated macrophages (TAMs). When isolated, 
Introduction
Emerging evidence indicates importance of inflammation in tumor initiation and progression. However, information on specific mechanisms or mediators of cancer-related inflammation in human cancers is still limited (1, 2) . Recent studies demonstrate that a substantial portion of inflammatory cells in human tumor tissues is represented by CD11b + myeloid cells that include large populations of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) (3) . TAMs represent an abundant and heterogeneous cell population in the tumor microenvironment and they play a key role in tumor development (4, 5) . For example, although M1-oriented TAMs constitute a critical component of the anti-tumor immune response, they are frequently subverted in the tumor microenvironment into alternatively activated M2 type that promotes tumor progression.
Chemokines and their receptors are involved in malignant progression (2, 6) . Some chemokines, like CCL1, CCL2, CCL17 and CCL22, have been shown to promote M2 and T h2 polarization in tumors that subvert the immune system by establishing a microenvironment of immune cells and cytokines that suppress specific anti-tumor responses. Hence, it is critical to study the mechanisms by which specific chemokines and their receptors mediate inflammatory cells traffic into tumor tissue and their functions. Despite the fact that chemokines are abundantly expressed in tumors, there is little information concerning chemokine-receptor expression in circulating or tumor-infiltrating leukocytes in human cancer patients.
CCR8 is a chemokine receptor that was initially described as a T h2 cell-restricted receptor (7, 8) . CCR8 is believed to mediate a broad range of cellular activities including T h2 and T regulatory cell recruitment in allergic inflammation (9, 10) , recruitment of inflammatory macrophages in mice with experimental hepatitis (11) , and chemotaxis of endothelial as well as vascular smooth muscle cells (12, 13) . These data suggest involvement of CCR8-expressing cells in inflammatory responses. However, whether CCR8 + cells contribute to cancer-related inflammation associated with progression of human cancers remains unknown.
In the current study we demonstrate that monocytic and granulocytic myeloid cells obtained from peripheral blood of patients with urothelial and renal carcinomas display increased expression of CCR8. Up-regulated expression of CCR8 was also detected in tumor-infiltrating leukocytes. Remarkably, CCR8 expression in cancer tissues was enriched in tumor-infiltrating CD11b myeloid cells and primarily to TAMs. We also found that the tumor-infiltrating 
Materials and Methods

Human subjects
Fifty two cancer patients (thirty patients with urothelial carcinoma of bladder and twenty two patients with renal cell carcinoma) were enrolled in this study. Detailed information on these cancer patients is shown in Supplementary Table S1 . Peripheral blood and tumor tissue were collected following cystectomy or nephrectomy procedures performed at the Department of Urology, University of Florida, Gainesville, FL. Control blood was collected from healthy donors. Clinical specimens were obtained following informed consent, as approved by the Institutional Review Board. All patients selected for the study were not previously treated with chemo-or adjuvant-therapy.
Assays
Reagents, cell isolation from peripheral blood and tumor tissues, preparation of tumorconditioned medium, Western blot analysis, Ca 2+ influx assay, RT-PCR analysis, flow cytometry, Multiplex cytokine assay and ELISA were performed as described in the section Supplemental Methods.
Statistical analysis
Values are expressed as mean ± SD. Unpaired Student t test was used to determine statistical significance between groups (GraphPad Prism; GraphPad Software, Inc). The criterion for significance was set at P < 0.05. The flow cytometry data shown are representative of at least three separate determinations.
Results
CCR8-expressing myeloid cell subset in peripheral blood of cancer patients
Tumors are known to secrete large amounts and a wide range of chemokines that affect function of host's immune and inflammatory cell subsets, including myeloid cells of bone marrow origin (14) . Given enhanced production of chemokines by tumors we hypothesized that in order to respond to those tumor-derived chemokines, some myeloid cell subsets in cancer 
Characterization of CCR8-expressing myeloid cells obtained from peripheral blood
We examined whether CCR8 is functional by treating peripheral blood mononuclear cells As shown in Fig. S2 blood of cancer patients with CCL1 had no effect on ROS production (data not shown).
In separate experiments, we found that expression of CCR8 also can be induced in myeloid cells by culturing them in the presence of primary bladder tumor-conditioned medium (TCM) ( Table S3 , B indicate that exposure of normal myeloid cells to the TCM promoted a strong increase in Stat3 phosphorylation, a relatively weak ERK phosphorylation, and no effect on Stat1 phosphorylation. Addition of Stat3 inhibitor S3I-201 completely prevented the TCM-mediated up-regulation of CCR8 in the myeloid cells (Fig. 2B) .
Distinctly, the inhibition of active ERK with U0126 or PD098059 showed no impact on the TCM-regulated expression levels of CCR8. These data indicate that TCM-induced CCR8 expression in myeloid cells depends on Stat3 activity.
To evaluate the immune function of CCR8-expressing cells, we examined effects of CCL1 on cytokine production by myeloid cells obtained from peripheral blood of cancer patients. To this end, CD11b + cells were isolated from PBMC of healthy donors and cancer patients and were cultured in the presence or absence of CCL1 for 24 hours. Cell supernatants were collected and analyzed for the presence of ten cytokines and chemokines, including IL-1β, TNF-α, IL-6, IL-8, VEGF, basic FGF, PDGF-BB, CCL2, CCL3 and CCL4 using Multiplex cytokine assay.
Obtained results indicate that treatment of peripheral myeloid cells from both bladder (Fig. 3A) and kidney ( Fig. 3B) cancer patients exhibited enhanced IL-6 production. Furthermore, we found that CCL1 stimulates IL-6 production by peripheral CD11b+ cells from cancer patients in a dosedependent manner ( Fig. 3C and Supplementary Fig. S3 ). Remarkably, CCL1-induced IL-6 production appears to be chemokine-specific and it was not observed following in vitro treatment with, for example, SDF-1 (Fig. 3D ).
CCR8 + cell subset can be found among CD11b myeloid cells infiltrating human cancer tissues
In addition to the peripheral blood, we also measured the levels of CCR8 expression in human tumor infiltrates ( We recently demonstrated that macrophage infiltrating human RCC exhibit potent regulatory activity (17) . Specifically, isolated TAMs were able to induce tolerogenic transcription factor FoxP3+ in T lymphocytes as well as to enhance IL-10 production. In order to evaluate the effects of CCR8 
Primary human cancers secrete large amounts of CCL1
Having demonstrated that expression of CCR8 in myeloid cells during tumor progression is increased, we next evaluated the levels of natural CCR8 ligand CCL1 in cancer patients.
Established human bladder and RCC cancer cell lines, freshly obtained primary bladder and kidney cancer tissues and CD11b cells isolated from RCC tissues were cultured for 24 hours.
Cell-free supernatants were collected and analyzed for CCL1 presence using commercial ELISA.
As shown in Fig. 6A , both bladder and RCC human cancer cell lines (SW780 and A498, respectively) did not secrete detectable levels of CCL1, while primary human tumors secreted substantial amounts of the chemokine (bladder cancer: 118 ± 44 pg/ml and renal carcinoma:
30.5 ± 7 pg/ml). Moreover, tumor-infiltrating myeloid CD11b+ cells were the primary source of CCL1 among the tumor cell suspension as CD11b+ myeloid cells isolated from renal carcinoma tissues produced 98 ± 36 pg/ml of CCL1. In addition, we measured levels of CCL1 in peripheral blood (plasma) obtained from cancer patients. Results indicate that levels of CCL1 in plasma of cancer patients with urothelial or renal carcinomas are very low (< 5 pg/ml) and in most cases undetectable (data not shown). These results indicate that primary human cancers secrete substantial amounts of CCL1 and tumor-infiltrating myeloid cells represent a major source of the chemokine.
To elucidate what cell subset among tumor-infiltrating CD11b cells produce CCL1, we measured CCL1 levels in CCR8+ and CCR8-myeloid cells isolated from human RCC tissues.
As can be seen in Fig. 6B , CCR8 -myeloid cells secreted significantly more CCL1 than CCR8 + subsets in three out four examined cancer patients. Therefore, it is likely that certain myeloid cell type among intra-tumoral CCR8 -CD11b cells (Fig. 4C) represents a major source of CCL1 in RCC tissue, suggesting existence of paracrine mechanisms involved in the regulation of CCL1-induced IL-6 production and CCR8 expression in tumor-infiltrating myeloid cells. A recent study demonstrated that CCL1 expression can be stimulated in human monocytes/macrophages by treatment with another chemokine (CXCL12) implying that CXCL12 could potentially promote elevated levels of CCL1 in tumor tissues (18) . Our data, however, indicate that primary RCC tumors secrete negligible levels of CXCL12 (data not shown).
IL-6 is known to induce Stat3 activation (19) . In previous experiments (Fig. 2) we demonstrated that CCR8 expression in myeloid cells is dependent upon Stat3 activation. -12-2091 in the CCR8 + than in their CCR8 -counterparts (Fig. 6C) . Together, these data demonstrate the CCR8-expressing myeloid cells have activated Stat3 and ERK pathways. 
Discussion
Despite recent advances in our understanding of the multiple roles of bone marrow-derived myeloid cells in tumor progression, heterogeneity of myeloid cells in tumor tissues as well as lack of specific markers for discrete cell subsets still represent significant obstacles for further progress. Establishing such biomarkers has the potential to enhance clinical prognosis and provide insights into relevant pathways of immune suppression utilized by the specific cancer.
In this study we measured expression of multiple chemokine receptors (CCR1, CCR2, CCR3 CCR4, CCR5, CCR6, CCR7, CCR8, CXCR2 and CXCR4) in myeloid cells obtained from peripheral blood of patients with bladder cancer and renal cell carcinoma. We found that among screened chemokine receptors only CCR8 expression was consistently and strongly up- In addition to the infiltration with CCR8-expressing myeloid cells, we also observed that primary human tumors secreted substantial amounts of CCL1. We found that RCC-infiltrating myeloid cells produced significantly higher amounts of CCL1 than whole RCC tissue or epithelial cancer cell lines. Previous studies demonstrated that CCL1 exhibits a unique pattern of regulation associated with a distinct form of M2 type monocyte activation that participates in macrophage-dependent regulatory circuits of innate and adaptive immunity (36). CCL1 also induces regulatory T cell recruitment (37) and promotes T h2 immune response (38, 39).
Interestingly, in mice subjected to chronic hepatic injury, CCR8-expressing liver macrophages were necessary for CCL1-directed migration of inflammatory, but not classically activated monocytes (11) . CCR8 deficiency also protected the liver against injury, ameliorating inflammatory responses and hepatic fibrogenesis. Furthermore, absence of CCR8 enhances Based on our results, we propose a working model for the contribution of CCR8-expressing myeloid cells to immune evasion in cancer (Fig. 6D) . CCL1 is produced primarily by After 24 hours cells were collected and expression of CCR8 was assessed using flow cytometry.
Results of one representative experiment out of three are shown. 
